Asian Journal of Medical Sciences,
Год журнала:
2024,
Номер
15(7), С. 137 - 141
Опубликована: Июль 1, 2024
Background:
Diabetic
dyslipidemia
poses
a
significant
risk
factor
for
cardiovascular
complications
in
patients
with
diabetes
mellitus.
Empagliflozin
and
liraglutide
are
two
commonly
used
medications
management,
yet
their
comparative
efficacy
safety
treating
diabetic
remain
under-explored.
Aims
Objectives:
This
study
aimed
to
assess
the
effectiveness
of
versus
managing
dyslipidemia.
Materials
Methods:
The
enrolled
100
participants
dyslipidemia,
divided
equally
into
empagliflozin
treatment
groups.
Baseline
characteristics,
including
age,
gender
distribution,
ethnicity,
duration
diabetes,
were
assessed
compared
between
Lipid
profiles,
encompassing
total
cholesterol,
low-density
lipoprotein
(LDL)
high-density
(HDL)
triglycerides,
evaluated
at
baseline
after
6
months
treatment.
Safety
outcomes,
such
as
occurrence
mild
gastrointestinal
symptoms,
hypoglycemia,
serious
adverse
events,
also
monitored.
Results:
Both
groups
exhibited
comparable
characteristics.
Following
treatment,
both
demonstrated
improvements
lipid
profiles.
Reductions
LDL
along
increases
HDL
observed
Moreover,
there
no
differences
events
groups,
indicating
similar
Conclusion:
provides
evidence
supporting
These
findings
highlight
potential
viable
therapeutic
options
Nature Medicine,
Год журнала:
2024,
Номер
30(10), С. 2849 - 2856
Опубликована: Июнь 24, 2024
Abstract
People
with
type
2
diabetes
and
chronic
kidney
disease
have
a
high
risk
for
failure
cardiovascular
(CV)
complications.
Glucagon-like
peptide-1
receptor
agonists
sodium-glucose
cotransporter-2
inhibitors
(SGLT2i)
independently
reduce
CV
events.
The
effect
of
combining
both
is
unclear.
FLOW
trial
participants
were
stratified
by
baseline
SGLT2i
use
(
N
=
550)
or
no
2,983)
randomized
to
semaglutide/placebo.
primary
outcome
was
composite
failure,
≥50%
estimated
glomerular
filtration
rate
reduction,
death
death.
the
24%
lower
in
all
treated
semaglutide
versus
placebo
(95%
confidence
interval:
34%,
12%).
occurred
41/277
(semaglutide)
38/273
(placebo)
on
at
(hazard
ratio
1.07;
95%
0.69,
1.67;
P
0.755)
290/1,490
372/1,493
not
taking
0.73;
0.63,
0.85;
<
0.001;
interaction
0.109).
Three
confirmatory
secondary
outcomes
predefined.
Treatment
differences
favoring
total
slope
(ml
min
−1
/1.73
m
/year)
0.75
(−0.01,
1.5)
subgroup
1.25
(0.91,
1.58)
non-SGLT2i
subgroup,
0.237.
Semaglutide
benefits
major
events
all-cause
similar
regardless
0.741
0.901,
respectively).
reducing
consistent
with/without
use;
power
limited
detect
smaller
but
clinically
relevant
effects.
ClinicalTrials.gov
identifier:
NCT03819153
.
Type
2
diabetes
mellitus
(T2DM)
is
a
chronic
disease
that
substantially
increases
morbidity
and
mortality
through
its
cardiovascular
renal
complications.
Beyond
mere
glycemic
control,
current
guidelines
from
the
European
Society
of
Cardiology
(ESC)
Kidney
Disease:
Improving
Global
Outcomes
(KDIGO)
recommend
interventions
confer
additional
benefits.
This
study
aims
to
assess
compare
efficacy
semaglutide
versus
empagliflozin
in
improving
weight,
blood
pressure,
function
patients
with
uncontrolled
T2DM
after
18
months
follow-up.
retrospective
cohort
included
41
(glycated
hemoglobin
(HbA1c)
>
7%)
who
received
either
(n=20)
or
(n=21)
as
monotherapy.
Clinical
laboratory
parameters
(HbA1c,
fasting
plasma
glucose,
body
systolic
diastolic
serum
creatinine,
estimated
glomerular
filtration
rate
(eGFR),
urine
microalbumin)
were
measured
at
baseline
(SEMPA18).
Changes
compared
between
two
groups
using
appropriate
statistical
methods.
Of
participants
(58.5%
male),
20
treated
21
semaglutide.
After
months,
median
HbA1c
decreased
7.60%
6.85%
group
(100%
improved)
7.90%
7.00%
(95.2%
improved).
A
reduction
weight
5%
more
was
achieved
by
(10.0%)
empagliflozin-treated
6
(28.6%)
among
those
on
(p=0.48).
Albuminuria
improved
(90.0%)
users
(median
final:
12.0
mg/dL)
14
(66.7%)
20.0
mg/dL),
although
difference
not
statistically
significant
(p=0.07).
Both
showed
gains
eGFR
(final
median:
80.50
vs.
71.00
mL/min/1.73
m²;
p=0.048),
creatinine
majority
(75.0%
71.4%).
subgroup
analysis
revealed
heart
failure
status
(LVEF
<
50%
documented
diagnosis)
associated
less
improvement
markers,
particularly
regardless
treatment
group.
In
this
real-world,
18-month
cohort,
produced
pronounced
improvements
albuminuria
slightly
greater
absolute
HbA1c,
whereas
trend
toward
loss,
though
significant.
These
findings
emphasize
individualized
therapy
choices
based
cardiorenal
risk
profiles
underscore
potential
value
early
initiation,
especially
higher
deterioration.
Cardiovascular Diabetology,
Год журнала:
2024,
Номер
23(1)
Опубликована: Июнь 1, 2024
regarding
the
CV
effects
of
oral
semaglutide
in
individuals
with
type
2
diabetes
and
established
ASCVD
and/or
CKD
[46]"
instead
"The
SOUL
study
demonstrated
non-inferiority
to
placebo
terms
mortality
outcomes
[46]".The
updated
Acknowledgements
statement
should
read,
"We
would
like
thank
BioQuest
Solutions
Pvt.Ltd
for
providing
medical
Asian Journal of Medical Sciences,
Год журнала:
2024,
Номер
15(7), С. 137 - 141
Опубликована: Июль 1, 2024
Background:
Diabetic
dyslipidemia
poses
a
significant
risk
factor
for
cardiovascular
complications
in
patients
with
diabetes
mellitus.
Empagliflozin
and
liraglutide
are
two
commonly
used
medications
management,
yet
their
comparative
efficacy
safety
treating
diabetic
remain
under-explored.
Aims
Objectives:
This
study
aimed
to
assess
the
effectiveness
of
versus
managing
dyslipidemia.
Materials
Methods:
The
enrolled
100
participants
dyslipidemia,
divided
equally
into
empagliflozin
treatment
groups.
Baseline
characteristics,
including
age,
gender
distribution,
ethnicity,
duration
diabetes,
were
assessed
compared
between
Lipid
profiles,
encompassing
total
cholesterol,
low-density
lipoprotein
(LDL)
high-density
(HDL)
triglycerides,
evaluated
at
baseline
after
6
months
treatment.
Safety
outcomes,
such
as
occurrence
mild
gastrointestinal
symptoms,
hypoglycemia,
serious
adverse
events,
also
monitored.
Results:
Both
groups
exhibited
comparable
characteristics.
Following
treatment,
both
demonstrated
improvements
lipid
profiles.
Reductions
LDL
along
increases
HDL
observed
Moreover,
there
no
differences
events
groups,
indicating
similar
Conclusion:
provides
evidence
supporting
These
findings
highlight
potential
viable
therapeutic
options
Biomolecules,
Год журнала:
2024,
Номер
15(1), С. 39 - 39
Опубликована: Дек. 31, 2024
Sodium-glucose
co-transporter
2
inhibitors
(SGLT2i),
glucagon-like
peptide-1
receptor
agonists
(GLP1a),
and
non-steroidal
mineralocorticoid
antagonists
(ns-MRA)
are
promising
treatments
for
chronic
kidney
disease.
This
umbrella
review
of
network
meta-analyses
evaluated
their
effects
on
cardiovascular
outcomes,
disease
progression,
adverse
events,
using
the
TOPSIS
method
to
identify
optimal
intervention
based
P-scores.
A
total
19
44
randomized
controlled
trials
involving
86,150
patients
were
included.
Compared
placebo,
SGLT2i
associated
with
reduced
risks
events
[Hazard
ratio
(HR):
0.776,
95%
confidence
intervals
(CI):
0.727–0.998],
progression
(HR:
0.679,
CI:
0.629–0.733),
acute
injury
0.873,
0.773–0.907),
serious
0.881,
0.847–0.916).
GLP1a
ns-MRA
also
significant
reductions
in
kidney-specific
composite
outcomes.
Indirect
evidence
showed
that
demonstrated
a
lower
risk
compared
0.826,
0.716–0.952)
0.818,
0.673–0.995),
representing
best
across
all
endpoints.
In
conclusion,
while
SGLT2i,
GLP1a,
reduce
disease,
appears
provide
most
favorable
balance
efficacy
safety.
